Home   About this service   Get the news  
+32 2 743 34 03

UCB [BE0003739530 / UCB]

UCB Media Room – UCB Showcases Wealth of new Psoriasis Research at EADV 2019


[09/10/2019 | 07:00]

** UCB Showcases Wealth of new Psoriasis Research at EADV 2019

=C2=B7 Data to be presented at EADV 2019 will further confirm the durabilit=
y of CIMZIA=C2=AE (certolizumab pegol) treatment in moderate-to-severe plaq=
ue psoriasis, including new three-year efficacy data
=C2=B7 New positive 60-week outcomes data from Phase 2 studies underscore t=
he potential of bimekizumab to improve scalp and nail psoriasis and health-=
related quality of life in psoriasis patients
=C2=B7 In total, UCB will present nine abstracts at the meeting, demonstrat=
ing the company=E2=80=99s ongoing commitment to improving the lives of peop=
le with psoriasis and psoriatic arthritis

Brussels, Belgium =E2=80=93 9 October 2019 =E2=80=93 UCB, a global biopharm=
aceutical company, today announced new data on the use of the Fc-free anti-=
TNF treatment, CIMZIA^=C2=AE (certolizumab pegol), in psoriasis and psoriat=
ic arthritis (PsA) will be presented at the 28th European Academy of Dermat=
ology and Venereology congress (EADV) in Madrid, October 9-13, 2019. Data i=
nclude three-year outcomes in psoriasis^1 and four-year results in PsA from=
the open-label extension studies of CIMZIA.^2 Additionally, the company wi=
ll share 60-week results^3,4 from the Phase 2 clinical development program =
of the company=E2=80=99s pipeline molecule bimekizumab =E2=80=93 a novel hu=
manized monoclonal IgG1 antibody that potently and selectively neutralizes =
both IL-17A and IL-17F cytokines, thought to be key drivers of psoriasis.^5

=E2=80=9CResults presented at EADV 2019 will reinforce and support the dura=
bility profile of CIMZIA efficacy in the treatment of both psoriasis and ps=
oriatic arthritis, and provide further evidence as to the exciting potentia=
l of bimekizumab in psoriasis,=E2=80=9D said Emmanuel Caeymaex, Head of Imm=
unology and Executive Vice President, Immunology Patient Value Unit, UCB. =
=E2=80=9CPatients with psoriasis deserve rapid and sustainable treatment re=
sults. The data we will share in Madrid show our commitment to delivering a=
gainst these key patient needs.=E2=80=9D

Reflecting UCB=E2=80=99s efforts to better understand the impact of psorias=
is on patients, and the unique needs of women, UCB will present new results=
from a sample of almost 90,000 respondents of the World Psoriasis Happines=
s Surveys. These findings highlight gender as a strong predictor of psychol=
ogical and social well-being in people living with psoriasis and PsA, more =
so than geographies. The analysis illustrates how psoriasis and PsA can neg=
atively affect women more than men when it comes to life satisfaction, lone=
liness, mood and self-esteem. Worse life satisfaction, stress, loneliness a=
nd isolation were felt most in young women with psoriasis.

New CIMZIA three-year efficacy data in plaque psoriasis from a pooled analy=
sis of the completed CIMPASI-1 and CIMPASI-2 open-label extension Phase 3 s=
tudies will be presented as an oral presentation at EADV 2019;^1 CIMZIA=E2=
=80=99s safety profile remains consistent with previously reported data.^1 =
Additional pooled results from these trials include CIMZIA 48-week sustaine=
d efficacy data in psoriasis of the head and neck, areas where disease mani=
festations can cause high degrees of emotional distress, particularly for f=
emale patients.^7 A post-hoc analysis of the four-year RAPID-PsA study will=
also be highlighted, showing durability of response of CIMZIA in PsA.^2 Th=
e ongoing focus on researching the long-term efficacy and safety of CIMZIA =
demonstrates how UCB continues its ongoing commitment to improving the live=
s of people with psoriasis.

New 60-week data on novel investigational molecule bimekizumab, from the BE=
ABLE Phase 2 clinical development program, will be shared in an oral prese=
ntation. The findings show rapid and sustained improvements in quality of l=
ife (as measured by the Dermatology Life Quality Index), which positively a=
ssociate with clinical outcomes in patients with moderate-to-severe plaque =
psoriasis.^3 Positive scalp and nail disease outcomes at 60 weeks will also=
be presented, further supporting bimekizumab=E2=80=99s potential.^4

The safety and efficacy of bimekizumab have not been established, and it is=
not approved by any regulatory authority worldwide.

Following is a guide to the UCB-sponsored data presentations:

UCB Sponsored Symposia:

Consider Tomorrow in Today=E2=80=99s Treatment Choice for Women Living with=
Psoriasis, M. Augustin, S. McBride, A. Egeberg

=C2=B7 Date/Time: October 10, 2019: 17:00-18:30 CEST
=C2=B7 Location: Hall Sorolla

Uncovering the potential of IL-17A and IL-17F dual neutralization in psoria=
sis, K. Papp, A. Armstrong, L. Iversen

=C2=B7 Date/Time: October 11, 2019: 17:00-18:30 CEST
=C2=B7 Location: Hall Sorolla

CIMZIA Oral Presentations:

Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Eff=
icacy Outcomes from the Intent-to-Treat Population of Two Phase 3 Trials (C=
IMPASI-1 and CIMPASI-2), K. Gordon, R. Warren, A. Gottlieb, A. Blauvelt, D.=
Tha=C3=A7i, C. Leonardi, Y. Poulin, M. Boehnlein, S. Kavanagh, C. Arendt, =
K. Reich

=C2=B7 Date/Time: October 10, 2019: 11:35-11:45 CEST
=C2=B7 Location: N109-110

Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Bu=
rden and Their Influence on the Safety Profile of Certolizumab Pegol across=
Indications, A. Blauvelt, V. Bykerk, J. Curtis, C. Gaujoux-Viala, T. Kvien=
, W. Sandborn, K. Winthrop, C. Popova, X. Mariette

=C2=B7 Date/Time: October 10, 2019: 15:50-16:00 CEST
=C2=B7 Location: N109-110

CIMZIA e-Posters:

Durability of Response in Patients with Psoriatic Arthritis Treated with Ce=
rtolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study=
, A. Gottlieb, P. Gisondi, J. Eells, L. Peterson, A. Kavanaugh

Efficacy of Certolizumab Pegol for Psoriasis of the Head and Neck in Two Ph=
ase 3 Clinical Trials: CIMPASI-1 and CIMPASI-2, P. van de Kerkhof, A. Pinte=
r, M. Boehnlein, S. Kavanagh, J. Crowley

Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in=
Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Tria=
ls (CIMPASI-1 and CIMPASI-2), K. Gordon, R. Warren, A. Gottlieb, A. Blauvel=
t, D. Tha=C3=A7i, C. Leonardi, Y. Poulin, M. Boehnlein, S. Kavanagh, C. Are=
ndt, K. Reich

Efficacy and Safety of Certolizumab Pegol in the Treatment of Japanese Pati=
ents With Psoriasis: Interim Week 24 Analyses from a 52-Week Phase 2/3, Ran=
domised, Placebo-Controlled Study, A. Asahina, Y. Umezawa, S. Sakurai, N. H=
oshii, H. Nakagawa

Bimekizumab Oral Presentations:

Bimekizumab provides rapid and sustained improvements in quality of life th=
at correlate with clinical outcomes in patients with moderate to severe pla=
que psoriasis: 60-week results from a randomised, double-blinded, Phase 2b =
extension study, K. Papp, J. Merola, A. Gottlieb, C. Griffiths, K. Harris, =
N. Cross, L. Peterson, C. Cioffi, A. Blauvelt

=C2=B7 Date/Time: October 10, 2019: 10:25-10:35 CEST
=C2=B7 Location: N109-110

Bimekizumab e-Poster:

Bimekizumab provides rapid and sustained improvements in scalp and nail out=
comes in patients with moderate-to-severe plaque psoriasis: 60-week results=
from a randomised, double-blinded, Phase 2b extension study, A. Blauvelt, =
K. Papp, J. Merola, A. Gottlieb, N. Cross, C. Madden, L. Peterson, C. Cioff=
i, C. Griffiths

UCB-Sponsored e-Poster on the Effect of Gender on the Impact of psoriasis:

Gender Differences in the Impact of Psoriasis: Results from the World Psori=
asis Happiness Surveys, S. McBride, C. Ecoffet, F. Fierens, M. Birkj=C3=A6r

About Bimekizumab
Bimekizumab is an investigational novel humanized monoclonal IgG1 antibody =
that potently and selectively neutralizes both IL-17A and IL-17F, two key c=
ytokines driving inflammatory processes.^8 IL-17A and IL-17F have similar p=
ro-inflammatory functions and independently cooperate with other inflammato=
ry mediators to drive chronic inflammation and damage across multiple tissu=

Previous early phase clinical studies in psoriasis and psoriatic arthritis =
have suggested that bimekizumab=E2=80=99s dual neutralization of both IL-17=
A and IL-17F may provide a new targeted approach for the treatment of immun=
e-mediated inflammatory diseases.^5,8,9 Preclinical results in disease-rele=
vant cells have shown that neutralizing IL-17F in addition to IL-17A reduce=
s skin and joint inflammation, as well as pathological bone formation to an=
extent greater than inhibition of IL-17A alone.^9,10,11

The safety and efficacy of bimekizumab have not been established, and it is=
not approved by any regulatory authority worldwide.

About CIMZIA^=C2=AE in the EU/EEA
In the EU, CIMZIA^=C2=AE in combination with methotrexate (MTX) is indicate=
d for the treatment of moderate to severe active RA in adult patients inade=
quately responsive to disease-modifying anti-rheumatic drugs (DMARDs) inclu=
ding MTX.

CIMZIA can be given as monotherapy in case of intolerance to MTX or when co=
ntinued treatment with MTX is inappropriate. CIMZIA in combination with MTX=
is also indicated for the treatment of severe, active and progressive RA i=
n adults not previously treated with MTX or other DMARDs.

CIMZIA has been shown to reduce the rate of progression of joint damage as =
measured by X-ray and to improve physical function, when given in combinati=
on with MTX.

CIMZIA, in combination with MTX, is also indicated for the treatment of act=
ive psoriatic arthritis in adults when the response to previous DMARD thera=
py has been inadequate. CIMZIA can be given as monotherapy in case of intol=
erance to MTX or when continued treatment with MTX is inappropriate.

CIMZIA is also indicated in the EU for the treatment of adult patients with=
severe active axial spondyloarthritis (axSpA), comprising:

=C2=B7 Ankylosing spondylitis (AS) =E2=80=93 adults with severe active AS w=
ho have had an inadequate response to, or are intolerant to non-steroidal a=
nti-inflammatory drugs (NSAIDs).
=C2=B7 Axial spondyloarthritis (axSpA) without radiographic evidence of AS =
=E2=80=93 adults with severe active axSpA without radiographic evidence of =
AS but with objective signs of inflammation by elevated C-reactive protein =
(CRP) and/or Magnetic Resonance Imaging (MRI) who have had an inadequate re=
sponse to, or are intolerant to NSAIDs.

CIMZIA is also indicated for the treatment of moderate to severe plaque pso=
riasis in adults who are candidates for systemic therapy.

About CIMZIA^=C2=AE in Fertility, Pregnancy and Lactation in the EU/EEA

Women of childbearing potential
The use of adequate contraception should be considered for women of childbe=
aring potential. For women planning pregnancy, continued contraception may =
be considered for 5 months after the last CIMZIA dose due to its eliminatio=
n rate, but the need for treatment of the woman should also be taken into a=
ccount (see below).
Data from more than 500 prospectively collected pregnancies exposed to CIMZ=
IA with known pregnancy outcomes, including more than 400 pregnancies expos=
ed during the first trimester, does not indicate a malformative effect of C=
IMZIA. However, the available clinical experience is too limited to, with a=
reasonable certainty, conclude that there is no increased risk associated =
with CIMZIA administration during pregnancy.
Animal studies using a rodent anti-rat TNF=CE=B1 did not reveal evidence of=
impaired fertility or harm to the foetus. However, these are insufficient =
with respect to human reproductive toxicity. Due to its inhibition of TNF=
=CE=B1, CIMZIA administered during pregnancy could affect normal immune res=
ponse in the newborn.
CIMZIA should only be used during pregnancy if clinically needed. Non-clini=
cal studies suggest low or negligible level of placental transfer of a homo=
logue Fab-fragment of certolizumab pegol (no Fc region).
In a clinical study 16 women were treated with certolizumab pegol (200 mg e=
very 2 weeks or 400 mg every 4 weeks) during pregnancy. Certolizumab pegol =
plasma concentrations measured in 14 infants at birth were Below the Limit =
of Quantification (BLQ) in 13 samples; one was 0.042 =C2=B5g/ml with an inf=
ant/mother plasma ratio at birth of 0.09%. At Week 4 and Week 8, all infant=
concentrations were BLQ. The clinical significance of low levels certolizu=
mab pegol for infants is unknown. It is recommended to wait a minimum of 5 =
months following the mother's last CIMZIA administration during pregnancy b=
efore administration of live or live-attenuated vaccines (e.g. BCG vaccine)=
, unless the benefit of the vaccination clearly outweighs the theoretical r=
isk of administration of live or live-attenuated vaccines to the infants.
In a clinical study in 17 lactating women treated with CIMZIA, minimal tran=
sfer of certolizumab pegol from plasma to breast milk was observed. The per=
centage of the maternal certolizumab pegol dose reaching an infant during a=
24 hour period was estimated to 0.04% to 0.30%. In addition, since certoli=
zumab pegol is a protein that is degraded in the gastrointestinal tract aft=
er oral administration, the absolute bioavailability is expected to be very=
low in a breastfed infant. Consequently, CIMZIA can be used during breastf=

Important Safety Information about CIMZIA^=C2=AE in the EU/EEA
Cimzia^=C2=AE was studied in 4,049 patients with rheumatoid arthritis (RA) =
in controlled and open label trials for up to 92 months. The commonly repor=
ted adverse reactions (1-10%) in clinical trials with Cimzia^=C2=AE and pos=
t-marketing were viral infections (includes herpeszoster, papillomavirus, i=
nfluenza), bacterial infections (including abscess), rash, headache (includ=
ing migraine), asthaenia, leukopaenia (including lymphopaenia, neutropaenia=
), eosinophilic disorder, pain (any sites), pyrexia, sensory abnormalities,=
hypertension, pruritus (any sites), hepatitis (including hepatic enzyme in=
crease), injection site reactions, and nausea. Serious adverse reactions in=
clude sepsis, opportunistic infections, tuberculosis (including miliary, di=
sseminated and extrapulmonary), herpes zoster, lymphoma, leukaemia, solid o=
rgan tumours, angioneurotic oedema, cardiomyopathies (includes heart failur=
e), ischemic coronary artery disorders, pancytopaenia, hypercoagulation (in=
cluding thrombophlebitis, pulmonary embolism), cerebrovascular accident, va=
sculitis, hepatitis/hepatopathy (includes cirrhosis), and renal impairment/=
nephropathy (includes nephritis). In RA controlled clinical trials, 4.4% of=
patients discontinued taking Cimzia^=C2=AE due to adverse events vs. 2.7% =
for placebo.

Cimzia^=C2=AE is contraindicated in patients with hypersensitivity to the a=
ctive substance or any of the excipients, active tuberculosis or other seve=
re infections such as sepsis or opportunistic infections and moderate to se=
vere heart failure.

Serious infections including sepsis, tuberculosis and opportunistic infecti=
ons (e.g. histoplasmosis, nocardia, candidiasis) have been reported in pati=
ents receiving Cimzia^=C2=AE. Some of these events have been fatal. Monitor=
patients closely for signs and symptoms of infections including tuberculos=
is before, during and after treatment with Cimzia^=C2=AE. Treatment with Ci=
mzia must not be initiated in patients with a clinically important active i=
nfection. If an infection develops, monitor carefully and stop Cimzia^=C2=
=AE until the infection is controlled. Before initiation of therapy with Ci=
mzia^=C2=AE, all patients must be evaluated for both active and inactive (l=
atent) tuberculosis infection. If active tuberculosis is diagnosed prior to=
or during treatment, Cimzia^=C2=AE therapy must not be initiated and must =
be discontinued. If latent tuberculosis is diagnosed, appropriate anti-tube=
rculosis therapy must be started before initiating treatment with Cimzia^=
=C2=AE. Patients should be instructed to seek medical advice if signs/sympt=
oms (e.g. persistent cough, wasting/weight loss, low grade fever, listlessn=
ess) suggestive of tuberculosis occur during or after therapy with Cimzia^=

Reactivation of hepatitis B has occurred in patients receiving a TNF-antago=
nist including Cimzia^=C2=AE who are chronic carriers of the virus (i.e. su=
rface antigen positive). Some cases have had a fatal outcome. Patients shou=
ld be tested for HBV infection before initiating treatment with Cimzia^=C2=
=AE. Carriers of HBV who require treatment with Cimzia^=C2=AE should be clo=
sely monitored and in the case of HBV reactivation Cimzia^=C2=AE should be =
stopped and effective anti-viral therapy with appropriate supportive treatm=
ent should be initiated.

TNF antagonists including Cimzia^=C2=AE may increase the risk of new onset =
or exacerbation of clinical symptoms and/or radiographic evidence of demyel=
inating disease, including multiple sclerosis; of formation of autoantibodi=
es and uncommonly of the development of a lupus-like syndrome; of severe hy=
persensitivity reactions. If a patient develops any of these adverse reacti=
ons, Cimzia^=C2=AE should be discontinued and appropriate therapy institute=

With the current knowledge, a possible risk for the development of lymphoma=
s, leukaemia or other malignancies in patients treated with a TNF antagonis=
t cannot be excluded. Rare cases of neurological disorders, including seizu=
re disorder, neuritis and peripheral neuropathy, have been reported in pati=
ents treated with Cimzia^=C2=AE.

Adverse reactions of the haematologic system, including medically significa=
nt cytopaenia, have been reported with Cimzia^=C2=AE. Advise all patients t=
o seek immediate medical attention if they develop signs and symptoms sugge=
stive of blood dyscrasias or infection (e.g., persistent fever, bruising, b=
leeding, pallor) while on Cimzia^=C2=AE. Consider discontinuation of Cimzia=
^=C2=AE therapy in patients with confirmed significant haematological abnor=

The use of Cimzia^=C2=AE in combination with anakinra or abatacept is not r=
ecommended due to a potential increased risk of serious infections. As no d=
ata are available, Cimzia^=C2=AE should not be administered concurrently wi=
th live vaccines. The 14-day half-life of Cimzia^=C2=AE should be taken int=
o consideration if a surgical procedure is planned. A patient who requires =
surgery while on Cimzia^=C2=AE should be closely monitored for infections.

Cimzia^=C2=AE was studied in 325 patients with active axial spondyloarthrit=
is (axSpA) and in 409 patients with psoriatic arthritis (PsA) for up to 4 y=
ears. The safety profile for axSpA and PsA patients treated with Cimzia^=C2=
=AE was consistent with the safety profile in RA and previous experience wi=
th Cimzia^=C2=AE.

Cimzia^=C2=AE was studied in 1112 patients with psoriasis in controlled and=
open-label studies for up to 18 months. The safety profile of Cimzia^=C2=
=AE 400 mg every 2 weeks and Cimzia^=C2=AE 200 mg every 2 weeks were genera=
lly similar.

Please consult the full prescribing information in relation to other side e=
ffects, full safety and prescribing information. European SmPC date of revi=
sion June 2019. https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-=

CIMZIA^=C2=AE is a registered trademark of the UCB Group of Companies.

For further information, UCB:

Corporate Communications
France Nivelle,
Global Communications, UCB
T +32.2.559.9178

Laurent Schots,
Media Relations, UCB
T +32.2.559.92.64

Investor Relations
Antje Witte,
Investor Relations, UCB
T +32.2.559.94.14

Communications Lead
Andrea Levin Christopher,
Immunology Communications, UCB
T +1.404.483.7329
andrea.christopher@ucb.com=C2=A0=C2=A0 =C2=A0

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases in immunol=
ogy and neurology. With 7,500 people in approximately 40 countries, the com=
pany generated revenue of =E2=82=AC 4.6 billion in 2018. UCB is listed on E=
uronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Forward looking statements - UCB
This press release contains forward-looking statements based on current pla=
ns, estimates and beliefs of management. All statements, other than stateme=
nts of historical fact, are statements that could be deemed forward-looking=
statements, including estimates of revenues, operating margins, capital ex=
penditures, cash, other financial information, expected legal, political, r=
egulatory or clinical results and other such estimates and results. By thei=
r nature, such forward-looking statements are not guarantees of future perf=
ormance and are subject to risks, uncertainties and assumptions which could=
cause actual results to differ materially from those that may be implied b=
y such forward-looking statements contained in this press release. Importan=
t factors that could result in such differences include: changes in general=
economic, business and competitive conditions, the inability to obtain nec=
essary regulatory approvals or to obtain them on acceptable terms, costs as=
sociated with research and development, changes in the prospects for produc=
ts in the pipeline or under development by UCB, effects of future judicial =
decisions or governmental investigations, product liability claims, challen=
ges to patent protection for products or product candidates, changes in law=
s or regulations, exchange rate fluctuations, changes or uncertainties in t=
ax laws or the administration of such laws and hiring and retention of its =
employees. UCB is providing this information as of the date of this press r=
elease and expressly disclaims any duty to update any information contained=
in this press release, either to confirm the actual results or to report a=
change in its expectations.
There is no guarantee that new product candidates in the pipeline will prog=
ress to product approval or that new indications for existing products will=
be developed and approved. Products or potential products which are the su=
bject of partnerships, joint ventures or licensing collaborations may be su=
bject to differences between the partners. Also, UCB or others could discov=
er safety, side effects or manufacturing problems with its products after t=
hey are marketed. Moreover, sales may be impacted by international and dome=
stic trends toward managed care and health care cost containment and the re=
imbursement policies imposed by third-party payers as well as legislation a=
ffecting biopharmaceutical pricing and reimbursement.

^1Gordon K, et al. Certolizumab Pegol for Treatment of Plaque Psoriasis: Po=
oled Three-Year Efficacy Outcomes from the Intent-to-Treat Population of Tw=
o Phase 3 Trials (CIMPASI-1 and CIMPASI-2). Abstract to be presented at EAD=
V 2019, 9-13 October, Madrid Spain.
^2Gottlieb A, et al. Durability of Response in Patients with Psoriatic Arth=
ritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses fro=
m the RAPID-PsA Study. Abstract to be presented at EADV 2019, 9-13 October,=
Madrid Spain.
^3Papp K, et al. Bimekizumab provides rapid and sustained improvements in q=
uality of life that correlate with clinical outcomes in patients with moder=
ate to severe plaque psoriasis: 60-week results from a randomised, double-b=
linded, Phase 2b extension study. Abstract to be presented at EADV 2019, 9-=
13 October, Madrid Spain.
^4Blauvelt A, et al. Bimekizumab provides rapid and sustained improvements =
in scalp and nail outcomes in patients with moderate-to-severe plaque psori=
asis: 60 week results from a randomised, double-blinded, Phase 2b extension=
study. Abstract to be presented at EADV 2019, 9-13 October, Madrid Spain.
^5Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation =
by bimekizumab in psoriatic arthritis: evidence from preclinical experiment=
s and a randomized placebo-controlled clinical trial that IL-17F contribute=
s to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523-532.
^6McBride S, et al. Gender Differences in the Impact of Psoriasis: Results =
from the World Psoriasis Happiness Surveys. Abstract to be presented at EAD=
V 2019, 9-13 October, Madrid Spain.
^7van de Kerkhof P, et al. Efficacy of Certolizumab Pegol for Psoriasis of =
the Head and Neck in Two Phase 3 Clinical Trials: CIMPASI-1 and CIMPASI-2. =
Abstract to be presented at EADV 2019, 9-13 October, Madrid Spain.
^8Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bim=
ekizumab, a humanized monoclonal antibody and selective dual inhibitor of I=
L-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991-10=
^9Papp K, Merola J, Gottlieb A, Griffiths C, Cross N, Peterson L, Cioffi C,=
Blauvelt A. Dual neutralization of both interleukin 17A and interleukin 17=
F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12=
-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am A=
cad Dermatol. 2018;79(2):277-286.e10.
^10Shah M, Maroof A, Al-Hosni R, Gikas P, Gozzard N, Shaw S, Roberts S. Bim=
ekizumab Blocks T Cell-Mediated Osteogenic Differentiation of Periosteal St=
em Cells: Coupling Pathological Bone Formation to IL-17A and IL-17F Signali=
ng [abstract]. Arthritis Rheumatol. 2017;69(suppl 10).
^11Maroof A, Okoye R, Smallie T, et al. Bimekizumab dual inhibition of IL-1=
7A and IL-17F provides evidence of IL-17F contribution to chronic inflammat=
ion in disease-relevant cells. Ann Rheum Dis. 2017;76(suppl.2):213-213.

UCB Showcases Wealth of new Psoriasis Research at EADV 2019 (https://u70611=
If you would rather not receive future communications from UCB SA, please g=
o to https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-2F12d8lSllQ=
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=